Gallium(III) Complex with Cloxyquin Ligands Induces Ferroptosis in Cancer Cells and Is a Potent Agent against Both Differentiated and Tumorigenic Cancer Stem Rhabdomyosarcoma Cells

0560039 - BFÚ 2023 RIV US eng J - Journal Article
Hreusová, Monika - Novohradský, Vojtěch - Marková, Lenka - Kostrhunová, Hana - Potočňák, I. - Brabec, Viktor - Kašpárková, Jana
Gallium(III) Complex with Cloxyquin Ligands Induces Ferroptosis in Cancer Cells and Is a Potent Agent against Both Differentiated and Tumorigenic Cancer Stem Rhabdomyosarcoma Cells.
Bioinorganic Chemistry and Applications. Roč. 2022, APR 23 2022 (2022), č. článku 3095749. ISSN 1565-3633. E-ISSN 1687-479X
R&D Projects: GA ČR(CZ) GA21-27514S
Institutional support: RVO:68081707
Keywords : TRIS(8-QUINOLINOLATO)GALLIUM(III) * THIOSEMICARBAZONES * POLYPHARMACOLOGY * ANTITUMOR * KP46
OECD category: Biochemistry and molecular biology
Impact factor: 3.8, year: 2022
Method of publishing: Open access
https://www.hindawi.com/journals/bca/2022/3095749/

In this work, gallium(III) complex with cloxyquin (5-chloro-8-quinolinol, HClQ) ligands is shown to effectively inhibit proliferation of rhabdomyosarcoma cells, the frequent, aggressive, and poorly treatable cancer of children. It offers striking selectivity to cancer cells compared to noncancerous human fibroblasts. The data reveal that the complex induces ferroptosis in rhabdomyosarcoma cells, likely due to interfering with iron metabolism. Importantly, it can kill both bulk and stem rhabdomyosarcoma cells. To the best of our knowledge, this is the first compound based on metal other than Fe capable of inducing ferroptosis in cancer cells.
Permanent Link: https://hdl.handle.net/11104/0340536